Compare ADMA Biologics Inc (ADMA) vs Southwest Airlines Co (LUV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Southwest Airlines Co — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Southwest Airlines Co trades at $48.5 (market cap $24.16B). The key difference: Southwest Airlines Co is far larger — about 11.3× ADMA Biologics Inc's market cap, and Southwest Airlines Co pays a 1.46% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | LUV | |
|---|---|---|
Market Cap | $2.13B | $24.16B |
Sector | Health | Industrials |
52-Week High | $20.38 | $54.80 |
52-Week Low | $7.60 | $29.06 |
Enterprise Value | $2.20B | $27.23B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Southwest Airlines (LUV) trades at $49.43, down 1.63% today, with a bullish technical signal from moving averages. The company reported revenue of $28.06B in 2025, with a net income margin of 2.83%, and has beaten earnings estimates in two of the last three quarters. Recent news highlights sector optimism due to lower fuel costs and strong travel demand, with analyst consensus leaning toward a buy rating and a $52.47 price target.
The outlook for LUV is cautiously optimistic, supported by earnings growth potential and favorable industry trends, but risks include volatile fuel prices and competitive pressures. The stock presents a moderate opportunity for investors seeking exposure to the airline sector, with upside to the consensus target but sensitivity to macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
